Efficacy and safety of dual antiplatelet treatment up to 72 hours after mild ischemic stroke or transient ischemic attack in patients with established cardiovascular disease.

Authors

Zhang Xia, Ying Gao, Weiqi Chen, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Xuan Wang, Peiyuan Gao, Hongyi Yan, Tingting Wang, Yingying Yang, Yanli Zhang, Yongjun Wang, Yilong Wang, Yuesong Pan

Published in

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. Volume 23. Issue 4. Pages e00963. Jul 10, 2026. Epub Jul 10, 2026.

Abstract

Patients with established cardiovascular disease (CVD) may have a higher risk of recurrent stroke and a higher prevalence of antiplatelet resistance than those without CVD. This study investigated the efficacy and safety of dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin in patients with established CVD. This is a secondary post hoc analysis of the Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial. Patients with mild ischemic stroke (IS) or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause were randomized to receive either DAPT or aspirin alone within 72 h after symptom onset. Established CVD was defined as a prior diagnosis of IS, coronary artery disease, TIA, or peripheral arterial disease. The primary efficacy and safety outcomes were the occurrence of new stroke and moderate-to-severe bleeding within 90 days. This study included 6100 patients, with a mean age of 63.7 ± 9.6 years and 35.8% of female. DAPT was associated with a reduced risk of new stroke (hazard ratio [HR] = 0.67, 95%CI: 0.54-0.85, P < 0.001) in non-CVD patients but not in those with established CVD (HR = 0.97, 95%CI: 0.73-1.28, P = 0.82), compared with aspirin (P for interaction = 0.04). Moderate-to-severe bleeding did not differ by antiplatelet treatments across CVD subgroups (P for interaction = 0.32). In the INSPIRES trial, patients with established CVD may benefit less from clopidogrel-aspirin in reducing the risk of recurrent stroke within 90 days than those without CVD after mild IS or high-risk TIA. TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.

PMID:
42430849
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.